After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?

Two recent patient deaths—both involving severe immune reactions to high-dose, viral vector-delivered gene therapies and a lack of disclosure—have drawn international scrutiny to what appear to be systemic gaps in oversight and transparency within China’s IIT framework.